ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.80991
0.09%
Brent Oil
84.205
0.30%
Bitcoin
62,858.05
-0.30%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Chemomab Therapeutics Ltd (CMMB)

  7. Chemomab Therapeutics Ltd (CMMB) Noticias

CMMB Chemomab Therapeutics Ltd

0.81
0.085 (11.72%)
09 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Chemomab Therapeutics Ltd CMMB NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.085 11.72% 0.81 23:00:02
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.735 0.6921 0.85 0.81 0.725
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/5/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202406:00GLOBEChemomab Therapeutics Announces First Quarter 2024 Financial..
08/5/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202406:00GLOBEChemomab Therapeutics Granted 180-Day Extension by Nasdaq to..
02/5/202406:00GLOBEChemomab Therapeutics to Present at 2024 Aegis Virtual..
24/4/202406:00GLOBEChemomab Therapeutics to Report First Quarter 2024 Financial..
18/4/202406:00GLOBEChemomab Reports New Peer-Reviewed Publication Reinforcing..
02/4/202406:00GLOBEChemomab to Host Virtual Key Opinion Leader Webinar on..
25/3/202406:06GLOBEChemomab Awarded New European Patent for CM-101, Its..
07/3/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202406:00PRNUSChemomab Therapeutics Announces Year End and Fourth Quarter..
05/3/202406:00PRNUSChemomab Therapeutics to Participate in Leerink Global..
20/2/202408:20APSBiotech Shares Massively Bid Up Before Opening Bell
20/2/202406:00PRNUSChemomab Awarded New Patents for CM-101, Its First-in Class..
14/2/202406:00PRNUSChemomab Therapeutics to Report Fourth Quarter and Full Year..
05/2/202406:00PRNUSChemomab Therapeutics to Participate in Upcoming Investor..
30/1/202406:00PRNUSChemomab Therapeutics Announces New Publication Reinforcing..
03/1/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/1/202406:00PRNUSChemomab Announces Completion of Patient Enrollment in..
16/11/202306:00PRNUSChemomab Presentation at ACR Convergence 2023 Provides..
15/11/202315:35EDGAR2Form SC 13D/A - General statement of acquisition of..
15/11/202306:00PRNUSChemomab Therapeutics Receives FDA Fast Track Designation..
13/11/202307:00PRNUSChemomab Presents New Clinical Data Supporting CM-101's..
09/11/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/11/202307:00PRNUSChemomab Therapeutics Announces Third Quarter 2023 Financial..
06/11/202315:15PRNUSChemomab Therapeutics Discloses Receipt of Nasdaq Notice..
05/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
30/10/202307:33EDGAR2Form F-3/A - Registration statement by foreign private..
30/10/202306:00PRNUSChemomab Therapeutics to Report Third Quarter 2023 Financial..
26/10/202306:00PRNUSChemomab Therapeutics to Present at Upcoming Scientific..
16/10/202315:25EDGAR2Form F-3 - Registration statement by foreign private issuers
28/9/202306:00PRNUSChemomab Therapeutics to Present Its CM-101 Clinical Program..
29/8/202306:00PRNUSChemomab Therapeutics to Present at the H.C. Wainwright 25th..
14/8/202307:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202307:00PRNUSChemomab Therapeutics Announces Second Quarter 2023..
08/8/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/7/202316:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202314:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/6/202306:00PRNUSChemomab Therapeutics Announces Publication in JCI Insight..
26/6/202306:00PRNUSChemomab Therapeutics Presents Data Reinforcing the Clinical..
21/6/202306:00PRNUSChemomab Therapeutics Reports Positive Data from Secondary..
05/6/202306:00PRNUSChemomab Therapeutics Announces Executive Leadership Changes..
02/6/202308:00PRNUSPatient Data Presented at 2023 EULAR Congress Highlights How..
24/5/202306:00PRNUSChemomab Therapeutics to Participate in Upcoming Scientific..
11/5/202305:00PRNUSChemomab Therapeutics Announces First Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
CMMB
Chemomab Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados